CMPI Key Statistics, Chart & Performance
The current stock price of CMPI is 10.5 null. In the past month the price increased by 1.16%. In the past year, price increased by 55.33%.
CMPI Latest News, Press Relases and Analysis
CMPI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.82 | 397.85B | ||
| AMGN | AMGEN INC | 15.43 | 181.73B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.52 | 107.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.67 | 78.84B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.29 | 60.05B | ||
| INSM | INSMED INC | N/A | 45.09B | ||
| NTRA | NATERA INC | N/A | 32.33B | ||
| BIIB | BIOGEN INC | 10.62 | 26.08B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| INCY | INCYTE CORP | 15.89 | 20.03B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About CMPI
Company Profile
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-08-07. The firm's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The firm is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The firm is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The firm's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.
Company Info
CHECKMATE PHARMACEUTICALS IN
245 Main Street, 2Nd Floor
Cambridge MASSACHUSETTS 02142 US
CEO: Barry Labinger
Employees: 30
Phone: 19785032124.0
CHECKMATE PHARMACEUTICALS IN / CMPI FAQ
Can you describe the business of CHECKMATE PHARMACEUTICALS IN?
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The company is headquartered in Cambridge, Massachusetts and currently employs 30 full-time employees. The company went IPO on 2020-08-07. The firm's product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle (VLP) utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The firm is conducting a Phase II trial of vidutolimod in combination with nivolumab (OPDIVO), in anti-PD-1 refractory melanoma. The firm is also conducting a randomized Phase II/III trial of vidutolimod in combination with nivolumab in first-line melanoma. The firm's VLP technology is designed to encapsulate and protect the CpG-A oligonucleotide from degradation in the tumor.
Can you provide the latest stock price for CHECKMATE PHARMACEUTICALS IN?
The current stock price of CMPI is 10.5 null. The price increased by 0.19% in the last trading session.
Does CMPI stock pay dividends?
CMPI does not pay a dividend.
What is the ChartMill technical and fundamental rating of CMPI stock?
CMPI has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting CMPI stock to perform?
8 analysts have analysed CMPI and the average price target is 12.75 null. This implies a price increase of 21.43% is expected in the next year compared to the current price of 10.5.
What is CHECKMATE PHARMACEUTICALS IN worth?
CHECKMATE PHARMACEUTICALS IN (CMPI) has a market capitalization of 231.40M null. This makes CMPI a Micro Cap stock.
When does CHECKMATE PHARMACEUTICALS IN (CMPI) report earnings?
CHECKMATE PHARMACEUTICALS IN (CMPI) will report earnings on 2022-08-10.
CMPI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CMPI. When comparing the yearly performance of all stocks, CMPI is one of the better performing stocks in the market, outperforming 99.74% of all stocks.
CMPI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CMPI. The financial health of CMPI is average, but there are quite some concerns on its profitability.
CMPI Financial Highlights
Over the last trailing twelve months CMPI reported a non-GAAP Earnings per Share(EPS) of -2.92. The EPS increased by 69.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.34% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
CMPI Forecast & Estimates
8 analysts have analysed CMPI and the average price target is 12.75 null. This implies a price increase of 21.43% is expected in the next year compared to the current price of 10.5.